177 related articles for article (PubMed ID: 26341741)
21. Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis.
Zeng P; Schmaier A
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911643
[TBL] [Abstract][Full Text] [Related]
22. Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy.
Neelakantan P; Marin D; Laffan M; Goldman J; Apperley J; Milojkovic D
Haematologica; 2012 Sep; 97(9):1444. PubMed ID: 22532521
[No Abstract] [Full Text] [Related]
23. Ponatinib circumvents FGF2-driven resistance to imatinib in CML.
Cancer Discov; 2014 Mar; 4(3):OF10. PubMed ID: 24596204
[TBL] [Abstract][Full Text] [Related]
24. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.
Jabbour E; Kantarjian H; Cortes J
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):323-34. PubMed ID: 25971713
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.
Okabe S; Tauchi T; Tanaka Y; Ohyashiki K
Biochem Biophys Res Commun; 2013 Jun; 435(3):506-11. PubMed ID: 23684619
[TBL] [Abstract][Full Text] [Related]
26. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
Kantarjian HM; Jabbour E; Deininger M; Abruzzese E; Apperley J; Cortes J; Chuah C; DeAngelo DJ; DiPersio J; Hochhaus A; Lipton J; Nicolini FE; Pinilla-Ibarz J; Rea D; Rosti G; Rousselot P; Shah NP; Talpaz M; Srivastava S; Ren X; Mauro M
Am J Hematol; 2022 Nov; 97(11):1419-1426. PubMed ID: 36054756
[TBL] [Abstract][Full Text] [Related]
27. Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation.
Giudice V; Ghelli Luserna di Rorà A; Serio B; Guariglia R; Giannini MB; Ferrari A; Simonetti G; Selleri C; Martinelli G
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33419251
[TBL] [Abstract][Full Text] [Related]
28. Codelivery of Ponatinib and SAR302503 by Active Bone-Targeted Polymeric Micelles for the Treatment of Therapy-Resistant Chronic Myeloid Leukemia.
Mu CF; Xiong Y; Bai X; Sheng YJ; Cui J
Mol Pharm; 2017 Jan; 14(1):274-283. PubMed ID: 27957861
[TBL] [Abstract][Full Text] [Related]
29. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
[No Abstract] [Full Text] [Related]
30. Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis.
Fachi MM; Tonin FS; Leonart LP; Aguiar KS; Lenzi L; Figueiredo BC; Fernandez-Llimos F; Pontarolo R
Eur J Cancer; 2018 Nov; 104():9-20. PubMed ID: 30296736
[TBL] [Abstract][Full Text] [Related]
31. Renovascular hypertension from the BCR-ABL tyrosine kinase inhibitor ponatinib.
Amin SO; Ruzicka M; Burns KD; Bence-Bruckler IA; Ryan SE; Hadziomerovic A; Hiremath S
J Clin Hypertens (Greenwich); 2020 Apr; 22(4):678-682. PubMed ID: 32175644
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the plasma concentration of ponatinib in a chronic myeloid leukaemia patient with ponatinib intolerance.
Abumiya M; Takahashi N; Yoshioka T; Kameoka Y; Miura M
J Clin Pharm Ther; 2021 Feb; 46(1):219-222. PubMed ID: 32985698
[TBL] [Abstract][Full Text] [Related]
33. An evaluation of ponatinib as a therapy in adult patients with resistant/intolerant chronic-phase chronic myeloid leukemia.
Yang J; Surapaneni M; Schiffer CA
Expert Rev Hematol; 2022 May; 15(5):393-402. PubMed ID: 35544670
[TBL] [Abstract][Full Text] [Related]
34. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.
Cortes J; Apperley J; Lomaia E; Moiraghi B; Undurraga Sutton M; Pavlovsky C; Chuah C; Sacha T; Lipton JH; Schiffer CA; McCloskey J; Hochhaus A; Rousselot P; Rosti G; de Lavallade H; Turkina A; Rojas C; Arthur CK; Maness L; Talpaz M; Mauro M; Hall T; Lu V; Srivastava S; Deininger M
Blood; 2021 Nov; 138(21):2042-2050. PubMed ID: 34407543
[TBL] [Abstract][Full Text] [Related]
35. Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia.
Haddad FG; Issa GC; Jabbour E; Yilmaz M
Expert Opin Pharmacother; 2022 May; 23(7):751-758. PubMed ID: 35412404
[TBL] [Abstract][Full Text] [Related]
36. Pityriasis Rubra Pilaris-Like Reaction Induced by a Tyrosine Kinase Inhibitor, the Ponatinib.
Mongereau M; Hillion B; Fouillard L; Boivin JF; Gaudron S
Am J Dermatopathol; 2021 May; 43(5):394-395. PubMed ID: 33264130
[No Abstract] [Full Text] [Related]
37. The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia.
Nazha A; Romo CG; Kantarjian H; Cortes J
Haematologica; 2013 Oct; 98(10):e131. PubMed ID: 24091930
[No Abstract] [Full Text] [Related]
38. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
Devos T; Havelange V; Theunissen K; Meers S; Benghiat FS; Gadisseur A; Vanstraelen G; Vellemans H; Bailly B; Granacher N; Lewalle P; De Becker A; Van Eygen K; Janssen M; Triffet A; Vrelust I; Deeren D; Mazure D; Bekaert J; Beck M; Selleslag D
Ann Hematol; 2021 Jul; 100(7):1723-1732. PubMed ID: 33942128
[TBL] [Abstract][Full Text] [Related]
39. Addendum to the German Consensus Recommendations on Ponatinib in the Treatment of Chronic Myeloid Leukemia.
Saussele S; La Rosée P; Kiani A; Haverkamp W; Jentsch-Ullrich K; Stegelmann F; Rieger C; Waller CF; Franke GN; Junghanss C; Kirchmair R; Theurl M; le Coutre P
Acta Haematol; 2024; 147(3):344-351. PubMed ID: 37848002
[TBL] [Abstract][Full Text] [Related]
40. Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations.
Melge AR; Kumar LG; K P; Nair SV; K M; C GM
J Biomol Struct Dyn; 2019 Nov; 37(18):4747-4766. PubMed ID: 30580670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]